Pathogenesis of atherogenic dyslipidemia

Research output: Contribution to journalArticle

Abstract

A major component of the insulin resistance syndrome is dyslipidemia. Alterations in serum lipid levels can be worsened by insulin resistance and represent a leading risk factor for the development of atherosclerotic cardiovascular disease. Cardiovascular risk factors, eg, smoking, hypertension, hyperglycemia, and other dyslipidemias, promote premature atherosclerosis when accompanied by some elevation of low-density lipoprotein (LDL). The clustering of many of these risk factors in individual patients is referred to as the metabolic syndrome, which is characterized by abnormally high levels of triglyceride-rich very low-density lipoprotein, low levels of high-density lipoprotein, and increased small LDL particles (the lipid triad), as well as hypertension, glucose intolerance, and a procoagulant state.

Original languageEnglish (US)
Pages (from-to)22-27
Number of pages6
JournalDrug Benefit Trends
Volume12
Issue numberSUPPL. A
StatePublished - 2000

Fingerprint

Dyslipidemias
LDL Lipoproteins
Insulin Resistance
Hypertension
Lipids
Glucose Intolerance
HDL Lipoproteins
Hyperglycemia
Cluster Analysis
Atherosclerosis
Cardiovascular Diseases
Smoking
Serum

Keywords

  • Cardiovascular risk factors
  • Dyslipidemia
  • Insulin resistance

ASJC Scopus subject areas

  • Leadership and Management
  • Pharmaceutical Science

Cite this

Pathogenesis of atherogenic dyslipidemia. / Grundy, Scott M.

In: Drug Benefit Trends, Vol. 12, No. SUPPL. A, 2000, p. 22-27.

Research output: Contribution to journalArticle

Grundy, SM 2000, 'Pathogenesis of atherogenic dyslipidemia', Drug Benefit Trends, vol. 12, no. SUPPL. A, pp. 22-27.
Grundy, Scott M. / Pathogenesis of atherogenic dyslipidemia. In: Drug Benefit Trends. 2000 ; Vol. 12, No. SUPPL. A. pp. 22-27.
@article{61a6b2450fe84cfd82258a9f81613b6e,
title = "Pathogenesis of atherogenic dyslipidemia",
abstract = "A major component of the insulin resistance syndrome is dyslipidemia. Alterations in serum lipid levels can be worsened by insulin resistance and represent a leading risk factor for the development of atherosclerotic cardiovascular disease. Cardiovascular risk factors, eg, smoking, hypertension, hyperglycemia, and other dyslipidemias, promote premature atherosclerosis when accompanied by some elevation of low-density lipoprotein (LDL). The clustering of many of these risk factors in individual patients is referred to as the metabolic syndrome, which is characterized by abnormally high levels of triglyceride-rich very low-density lipoprotein, low levels of high-density lipoprotein, and increased small LDL particles (the lipid triad), as well as hypertension, glucose intolerance, and a procoagulant state.",
keywords = "Cardiovascular risk factors, Dyslipidemia, Insulin resistance",
author = "Grundy, {Scott M}",
year = "2000",
language = "English (US)",
volume = "12",
pages = "22--27",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "SUPPL. A",

}

TY - JOUR

T1 - Pathogenesis of atherogenic dyslipidemia

AU - Grundy, Scott M

PY - 2000

Y1 - 2000

N2 - A major component of the insulin resistance syndrome is dyslipidemia. Alterations in serum lipid levels can be worsened by insulin resistance and represent a leading risk factor for the development of atherosclerotic cardiovascular disease. Cardiovascular risk factors, eg, smoking, hypertension, hyperglycemia, and other dyslipidemias, promote premature atherosclerosis when accompanied by some elevation of low-density lipoprotein (LDL). The clustering of many of these risk factors in individual patients is referred to as the metabolic syndrome, which is characterized by abnormally high levels of triglyceride-rich very low-density lipoprotein, low levels of high-density lipoprotein, and increased small LDL particles (the lipid triad), as well as hypertension, glucose intolerance, and a procoagulant state.

AB - A major component of the insulin resistance syndrome is dyslipidemia. Alterations in serum lipid levels can be worsened by insulin resistance and represent a leading risk factor for the development of atherosclerotic cardiovascular disease. Cardiovascular risk factors, eg, smoking, hypertension, hyperglycemia, and other dyslipidemias, promote premature atherosclerosis when accompanied by some elevation of low-density lipoprotein (LDL). The clustering of many of these risk factors in individual patients is referred to as the metabolic syndrome, which is characterized by abnormally high levels of triglyceride-rich very low-density lipoprotein, low levels of high-density lipoprotein, and increased small LDL particles (the lipid triad), as well as hypertension, glucose intolerance, and a procoagulant state.

KW - Cardiovascular risk factors

KW - Dyslipidemia

KW - Insulin resistance

UR - http://www.scopus.com/inward/record.url?scp=0033898220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033898220&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033898220

VL - 12

SP - 22

EP - 27

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - SUPPL. A

ER -